BioStratum Names Schotzinger Vice President and Chief Medical Officer
-- Abbott VP, Hospital Products Division, Joins BioStratum --

Research Triangle Park, NC, November 7, 2000 - BioStratum Incorporated has named Robert Schotzinger, M.D., Ph.D. vice president and chief medical officer. Dr. Schotzinger joins BioStratum from Abbott Laboratories where he held positions of increasing responsibility in Abbott's International Division before assuming his most recent position as divisional vice president of pharmaceutical and clinical development at the Hospital Products Division of Abbott.

"We are very pleased to have Bob Schotzinger join the BioStratum team because he brings substantial skills in clinical development as well as a wealth of knowledge related to all aspects of pharmaceutical development that will be invaluable to us as we continue to grow," said Dr. Claus Kuhl, president and chief executive officer of BioStratum.

At BioStratum, Dr. Schotzinger assumes responsibility for drug development activities and will oversee ongoing and future clinical trials of BioStratum's drug candidates. While at Abbott he oversaw development of a broad based product line and helped stimulate new business development through his involvement in licensing multiple pharmaceutical compounds across key business areas. He also was directly involved with international initiatives that resulted in the licensing and approval of numerous products.

BioStratum Incorporated is the world leader in basal lamina research. The basal lamina is a thin membrane that separates and directs the function of cells and tissues throughout the body serving as the tissue's "biological operating system." More than two decades of research have uncovered the basal lamina's central role in diseases for which effective treatments are not currently available.

The company's lead drug candidate, Pyridorin™, is currently advancing through clinical trials for diabetic kidney disease. Angiocol™, its proprietary anti-angiogenesis agent, dramatically inhibits the growth of tumors in animal studies, and, pending approval from the FDA, will soon begin clinical trials. Novel therapeutic targets have also been identified for autoimmune and kidney diseases.

In its most recent round of private financing, the company raised $28 million to fund clinical trials, expand in-house drug development capabilities, and increase funding and staffing at its headquarters and its research subsidiary in Stockholm, Sweden, BioStratum AB.

Headquartered in Research Triangle Park, North Carolina, BioStratum's research and development operations are further expanded through corporate sponsored research programs. These programs are conducted with institutions that are centers of excellence in the basal lamina field, such as the Karolinska Institute in Stockholm, Sweden and the University of Kansas Medical Center, Kansas City, Kansas.

###